Front > Mergers & acquisitions

Mergers & acquisitions

Ori Yehudai  photo: Eyal Izhar Frutarom acquires Argentinean flavors co Meroar

The fast-growing Israeli flavors and natural specialty fine ingredients company has made 37 acquisitions since 2013.

Uri Geiger and Mori Arkin Photos: PR and Jonathan Bloom Accelmed fund makes 250% on Cogentix exit

Cogentix, sold to Canadian company Laborie for $242 million, is the biggest success so far for Accelmed's investment model.

Udi Mokady CEO CyberArk CyberArk acquires cloud security co Vaultive

The Petah Tikva based cybersecurity company says Vaultive's cloud security product will enhance its privileged account security solution.

IMI Systems Elbit Systems to acquire IMI Systems for NIS 1.8b

Israel's Ministry of Finance has reached agreement with Elbit Systems over the privatization of Israel Military Industry (IMI) Systems.

Naty Saidoff  photo: Avi Shauly Saidoff presses banks to intervene in Bezeq board battle

Unless acquiring Eurocom gives him control of Bezeq, Naty Saidoff is likely to withdraw, leaving the creditor banks without a debt arrangement.

Vonetize Smart VOD Photo: PR US movie studio to buy Israeli smart VOD co Vonetize

The US company will buy the first 10% of Vonetize for $1.41 per share, a 490% premium on the share price, reflecting a company valuation of $50 million.

Negev Ceramics Photo: Eyal Yitzhar Jordanian lifeline for Negev Ceramics

Businessman Moshe Sabah who is leading a consortium: Money for Negev Ceramics acquisition will come from a Jordanian investor.

Gil Agmon  photo: Eyal Izhar Delek Motors acquiring 70% of Veridis for NIS 1b

Veridis deals in the environment, desalination, power production, and energy solutions.

Dr. Stefan Oschmann  photo: Shlomi Yosef Merck KGaA showing Teva the way?

Merck CEO Dr. Stefan Oschmann is reluctant to comment on Teva, but comparisons are inevitable.

Eduardo Elsztain  photo: Eyal Izhar Elsztain's plan: Buy Bezeq low, sell Cellcom high

The IDB controlling shareholder believes that Cellcom's share price is as high as it can get.

Yoni Heilbronn and Ofer Ben-Noon  photo: Shlomi Yosef How Argus drove to the exit

Argus's CEO and CMO talk about their competitive advantage and how they might expand from car cybersecurity.

Prof. Zelig Eshar Photo: Shlomi Yosef Israeli professors fight for Kite Pharma sale spoils

Prof. Gideon Gross is suing Prof. Zelig Eshhar, alleging that Eshhar cheated him out of his share of the $11.9 billion sale of Kite, which has developed a revolutionary cancer drug.

Arie Belldegrun Photo: PR "Chemotherapy will become just a bad memory"

More energetic than ever, Arie Belldegrun talks to "Globes" about Kite Pharma's remarkable journey and the future of cancer treatment.

Mori Arkin, Uri Geiger photos: Tamar Matsafi, Eyal Izhar Accelmed fattening Cogentix for sale

Accelmed seeks to replicate its success formula in urology, as portfolio company Cogentix makes a third acquisition.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018